ArticleFrontiers in endocrinology2025
Morning spot urinary cortisol-to-creatinine ratio: a novel screening tool for assessing excess cortisol secretion.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Current screening methods for hypercortisolism face limitations in clinical practice. Objective: Our study proposes and validates a novel biomarker, the morning spot urinary cortisol-to-creatinine ratio (UCCR), as a simpler alternative for assessing excess cortisol secretion. Methods: This cross-sectional study was conducted in Chinese hospitalized patients, comprising a cohort of 167 patients who underwent the 1mg overnight dexamethasone suppression test (1mg DST). Urinary free cortisol level (UFC) and creatinine were measured using morning spot urine, and UCCR was subsequently calculated. Receiver operating characteristic (ROC) curve analysis was used to assess the performance of these parameters in predicting the results of the 1mg DST. Results: Morning spot UCCR showed significant correlations with 24-hour UFC and was independently associated with a positive 1mg DST result. The ROC AUCs for morning spot UCCR were 0.642 (0.549-0.734) and 0.762 (0.665-0.859) in predicting cortisol >1.8 µg/dL and >5.0 µg/dL post-1mg DST, respectively, comparable to those of 24-hour UFC and UCCR. Morning spot UCCR demonstrated high sensitivity of 71.4% and 86.4% for predicting post-DST cortisol >1.8 µg/dL and 5.0 µg/dL, respectively. The negative predictive value (NPV) of morning spot UCCR was 83.5% for cortisol >1.8 µg/dL and 96.8% for >5.0 µg/dL post-1mg DST. A significant reduction in ROC AUC was observed in males, with a borderline decrease noted in patients with diabetes. Conclusions: Morning spot UCCR is a reliable alternative for the initial evaluation of cortisol secretion and is particularly useful for excluding cortisol excess. Nonetheless, caution is advised when applying this test in males or patients with diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.